Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Queensland Health
Johnson and Johnson
Baxter
Harvard Business School
Cantor Fitzgerald
Mallinckrodt
McKesson
Chubb
Teva

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,365,205

« Back to Dashboard

Which drugs does patent 7,365,205 protect, and when does it expire?

Patent 7,365,205 protects SAVAYSA and is included in one NDA.

This patent has fifty-six patent family members in twenty-four countries.
Summary for Patent: 7,365,205
Title:Diamine derivatives
Abstract: A compound represented by the general formula (1): Q.sup.1-Q.sup.2-T.sup.0-N(R.sup.1)-Q.sup.3-N(R.sup.2)-T.sup.1-Q.sup.4 (1) wherein R.sup.1 and R.sup.2 are hydrogen atoms or the like; Q.sup.1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q.sup.2 is a single bond or the like; Q.sup.3 is a group ##STR00001## in which Q.sup.5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T.sup.0 and T.sup.1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.
Inventor(s): Ohta; Toshiharu (Tokyo, JP), Komoriya; Satoshi (Tokyo, JP), Yoshino; Toshiharu (Tokyo, JP), Nagamochi; Masatoshi (Tokyo, JP), Ono; Makoto (Tokyo, JP)
Assignee: Daiichi Sankyo Company, Limited (Tokyo, JP)
Application Number:10/481,262
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 7,365,205

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Daiichi Sankyo Inc SAVAYSA edoxaban tosylate TABLET;ORAL 206316-001 Jan 8, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Daiichi Sankyo Inc SAVAYSA edoxaban tosylate TABLET;ORAL 206316-002 Jan 8, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Daiichi Sankyo Inc SAVAYSA edoxaban tosylate TABLET;ORAL 206316-003 Jan 8, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,365,205

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2001-187105Jun 20, 2001
Japan2001-243046Aug 9, 2001
Japan2001-311808Oct 9, 2001
Japan2001-398708Dec 28, 2001
PCT Information
PCT FiledMarch 20, 2002PCT Application Number:PCT/JP02/02683
PCT Publication Date:January 03, 2003PCT Publication Number: WO03/000657

Non-Orange Book US Patents Family Members for Patent 7,365,205

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,342,014 Diamine derivatives ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,365,205

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I298066 ➤ Subscribe
Russian Federation 2319699 ➤ Subscribe
Russian Federation 2004101279 ➤ Subscribe
Russian Federation 2314303 ➤ Subscribe
Russian Federation 2004106625 ➤ Subscribe
Portugal 1405852 ➤ Subscribe
Poland 368402 ➤ Subscribe
Poland 220739 ➤ Subscribe
Poland 398653 ➤ Subscribe
Poland 214669 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Cipla
Federal Trade Commission
US Department of Justice
Harvard Business School
Daiichi Sankyo
Chubb
Cantor Fitzgerald
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot